Spotlight on CIDP: Evolving Perspectives on Disease Management
Navigating Management Challenges, Scientific Progress, and Practical Patient Care The understanding of chronic inflammatory demyelinating polyneuropathy (CIDP) is evolving from a clinically defined disease to a dynamic biological continuum. As a result, the spotlight is shifting towards identifying the underlying drivers of residual disability as early as possible, with the goal of influencing the disease course.
Note from the speakers
ITU Highlights
BioBook
AAN, American Academy of Neurology; CIDP, chronic inflammatory demyelinating polyneuropathy; CDT, central daylight time; GBS, Guillian-Barre Syndrome; HIV, human immunodeficiency virus; JPNS, Journal of the Peripheral Nerve Society. This program is NOT accredited for continuing medical education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2026 AAN Annual Meeting. This is a non-promotional medical symposium sponsored by Sanofi. The content was developed by Sanofi in consultation with scientific experts for scientific exchange purposes and is not eligible for CME credits. This event is for HCPs only.